JPMorgan Chase & Co’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $345K | Buy |
25,500
+4,946
| +24% | +$66.9K | ﹤0.01% | 4215 |
|
|
2025
Q1 | $326K | Sell |
20,554
-483,036
| -96% | -$7.67M | ﹤0.01% | 4244 |
|
|
2024
Q4 | $6.2M | Buy |
503,590
+482,174
| +2,251% | +$5.94M | ﹤0.01% | 2607 |
|
|
2024
Q3 | $259K | Sell |
21,416
-685
| -3% | -$8.3K | ﹤0.01% | 4361 |
|
|
2024
Q2 | $259K | Buy |
22,101
+3,363
| +18% | +$39.3K | ﹤0.01% | 4145 |
|
|
2024
Q1 | $242K | Sell |
18,738
-4,825
| -20% | -$62.3K | ﹤0.01% | 4363 |
|
|
2023
Q4 | $203K | Buy |
23,563
+14,479
| +159% | +$125K | ﹤0.01% | 4440 |
|
|
2023
Q3 | $86.4K | Sell |
9,084
-1,736
| -16% | -$16.5K | ﹤0.01% | 4702 |
|
|
2023
Q2 | $184K | Buy |
10,820
+1,551
| +17% | +$26.4K | ﹤0.01% | 4317 |
|
|
2023
Q1 | $145K | Buy |
+9,269
| New | +$145K | ﹤0.01% | 4495 |
|